A pineal “longevity” tetrapeptide — with an evidence base that hinges on one research group
Research compound
Epitalon (also spelled epithalon) is not approved by the FDA and its anti-aging claims are not established by independent trials. Anything sold under this name is an unregulated research chemical. This page is educational, not medical advice.
Class
Pineal tetrapeptide
Sequence
Ala-Glu-Asp-Gly
FDA Status
Not approved
Epitalon is a synthetic tetrapeptide — four amino acids, Ala-Glu-Asp-Gly — designed as the active fragment of epithalamin, an extract of the pineal gland. It was developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology in Russia. The interest around it comes from claims that it activates telomerase (the enzyme that maintains the protective caps on chromosomes), normalizes circadian and melatonin rhythms, and extends lifespan.
There is a genuine body of published work on epitalon and telomerase, including cell-culture reports of telomere elongation and animal studies reporting lifespan effects. The catch is central to reading any of it honestly: the large majority of this research originates from Khavinson's own group. Independent replication by unaffiliated labs is limited, and there are no large, controlled human longevity trials. In evidence terms, a single-source literature is a caution flag, not a confirmation.
Epitalon is one of the most-hyped “longevity” peptides, and the hype rests on a real but narrow, largely single-source evidence base. That is not the same as proof, and it is not a substitute for the boring, well-studied levers of healthy aging. Treat it as investigational and unproven.
If you're tracking a protocol, do it privately and honestly. Jabbit is an ad-free injection log — no data selling, no hype.
Download on App Store